A phase i study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: A Wisconsin oncology network study

Investigational New Drugs

Volumn 31, Issue 4, 2013, Pages 943-948

  Loconte, Noelle K ^a   Holen, Kyle D ^a   Schelman, William R ^a   Mulkerin, Daniel L ^a   Deming, Dustin A ^a   Hernan, Hilary R ^a   Traynor, Anne M ^a   Goggins, Timothy ^b   Groteluschen, David ^c   Oettel, Kurt ^d   Robinson, Emily ^e   Lubner, Sam J ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b Fox Valley Hematology Oncology Associates   (United States)

^c Green Bay Oncology   (United States)

^d GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^e MERCY HEALTH SYSTEM   (United States)

Author keywords

Bile duct cancer; Capecitabine; Chemotherapy; Oxaliplatin; Pancreatic cancer; Sorafenib

Indexed keywords

CAPECITABINE; CISPLATIN; GEMCITABINE; OXALIPLATIN; SORAFENIB;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BILIARY TRACT CANCER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHOLECYSTECTOMY; CLINICAL ARTICLE; COHORT ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GALLBLADDER CANCER; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PANCREAS CANCER; PERITONEUM METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; DEMOGRAPHY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PHENYLUREA COMPOUNDS; TREATMENT OUTCOME; WISCONSIN;

EID: 84880921318     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9916-5     Document Type: Article

References (30)

1. Baselga J, Roche H, Costa F, et al (2009) SOLTI-0701: A multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer. Cancer Research; 69:Abstract 45
2. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). CTEP, 2006. (Accessed at http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ docs/ctcaev3.pdf)
3. Conroy T, Desseigne F, Ychou M et al (2010) Randomized phase III trial comparing FOLFIRINOX versus gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma: preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. Proc Am Soc Clin Oncol 28:4010, abstract
4. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825
5. Coriat R, Mir O, Cessot A, et al (2010) Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. Investigational New Drugs
6. El-Khoueiry AB, Ramanathan RK, Yang DY, Zhang W, Shibata S, Wright JJ, Gandara D, Lenz HJ (2012) A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Investig New Drugs 39(3):1175-1183
7. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K (2008) Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Canc Sci 99:159-165
8. Ghosn M, Farhat F, Kattan J et al (2007) FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer. Am J Clin Oncol 30:15-20
9. Glover K, Thomas M, Brown T, et al (2005) A phase II study of oxaliplatin and capecitabine in patients with unresectable cholangiocarcinoma, including carcinoma of the gallbladder and biliary tract. Proc Am Soc Clin Oncol
10. Grothey A, Cutsem EV, Sobrero A, et al (2012) Regorafenib monotherapy for previously treatment metastatic colorectal cancer (CORRECT): an international, multicentre, randomized, placebo-controlled, phase 3 trial. Lancet; e-pub Nov. 21, 2012
11. Holcombe RF, Gu M, Imagawa D, Milovanovic T (2003) Expression of Kit and platelet-derived growth factor receptors alpha and beta in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571). Anti canc Drug 14:651-657
12. Hruban RH, van Mansfeld AD, Offerhaus GJ et al (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143:545-554
13. Knox JJ, Hedley D, Oza A et al (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23:2332-2338
14. Kulke MH, Blaszkowsky LS, Ryan DP et al (2007) Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25:4787-4792
15. Kupsch P, Henning BF, Passarge K et al (2005) Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 5:188-196
16. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
17. Moore M, Goldstein J, Hamm A (2005) Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Cancer Clinical Trials Group (NCIC-CTG). Proc Amer Soc Clin Oncol
18. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966
19. Mulkerin D, LoConte N, Holen K, et al (2009) A phase I study of an oral simulated FOLFOX with high dose capecitabine. Investigational New Drugs
20. Pelzer U, Kubica K, Stieler J et al (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO-003 study. Proc Am Soc Clin Oncol 26:4508
21. Reuben DB, Herr, KA, Pacala JT (2005) Geriatrics At Your Fingertips. 7th ed: American Geriatrics Society
22. Richly H (2006) Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 17:866-873
23. Riechelmann RP, Townsley CA, Chin SN, Pond GR, Knox JJ (2007) Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 110:1307-1312
24. Siu LL, Awada A, Takimoto CH et al (2006) Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 12:144-151
25. Tang D, Nagano H, Yamamoto H et al (2006) Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep 15:525-532
26. Therasse P, Arbuck S, Elizabeth A, Eisenhauer JW, Richard S, Kaplan LR, Verweij J, Martine Van G, Allan T, van Oosterom MCC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Canc Inst 92:205-216
27. Tsavaris N, Kosmas C, Skopelitis H et al (2005) Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Investig New Drugs 23:369-375
28. Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273-1281
29. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129-3140
30. Yu C, Bruzek LM, Meng XW et al (2005) The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24:6861-6869